Board Member
Puma Biotechnology, Inc. (PBYI)Equibles does not estimate personal net worth.
Get an email with a short summary when Puma Biotechnology, Inc. publishes a filing, an earnings call transcript or a press release.
Get PBYI alertsAlan Auerbach is recorded as Board Member at Puma Biotechnology, Inc. (PBYI) since January 1, 2010 and CEO at Puma Biotechnology, Inc. (PBYI). The proxy statement of Puma Biotechnology, Inc. reports total compensation of $3,062,337 for Alan Auerbach in fiscal 2025, including a base salary of $931,333. Disclosed compensation is on record for 9 fiscal years. Alan Auerbach has spoken on 25 earnings calls and 1 other investor event across 1 company, most recently for Puma Biotechnology, Inc. on September 14, 2026. Puma Biotechnology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Puma Biotechnology, Inc. includes Alan H. Auerbach (CEO and Board Member), Maximo Nougues (CFO), Adrian M. Senderowicz (Board Member) and 6 others.
“Today, Puma reported total revenue for the second quarter of 2026 of $56.5 million. Total revenue includes product revenue net, which consists entirely of Neuralink sales, as well as royalties from our sublicensees.”
“Today, Puma reported total revenue for the second quarter of 2026 of $56.5 million. Total revenue includes product revenue net, which consists entirely of Neuralink sales, as well as royalties from our sublicensees.”
“Today, Puma reported total revenue for the first quarter of 2026 of $44.8 million. Total revenue includes product revenue net, which consists entirely of near-link sales, as well as royalties from our sub-licensees.”
“Puma reported total revenue for the fourth quarter of 2025 of $75.5 million. Total revenue includes product revenue net, which consists entirely of NERLYNX sales as well as royalties from our sub-licensees.”
“Today, Puma reported total revenue for the third quarter of 2025 of $54.5 million. Total revenue includes product revenue net, which consists entirely of NERLYNX sales as well as royalties from our sub-licensees.”
2010-01-01–present
Biotechnology · Healthcare
CEO, Board Member
2010-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Puma Biotechnology, Inc. (PBYI) | CEO | $931,333 | $3,062,337 |
| 2024 | Puma Biotechnology, Inc. (PBYI) | CEO | $904,207 | $3,969,931 |
| 2023 | Puma Biotechnology, Inc. (PBYI) | CEO | $877,871 | $2,944,748 |
| 2022 | Puma Biotechnology, Inc. (PBYI) | CEO | $852,302 | $2,532,761 |
| 2021 | Puma Biotechnology, Inc. (PBYI) | CEO | $827,478 | $18,453,610 |
| 2020 | Puma Biotechnology, Inc. (PBYI) | CEO | $834,276 | $4,413,827 |
| 2019 | Puma Biotechnology, Inc. (PBYI) | CEO | $779,978 | $3,755,322 |
| 2018 | Puma Biotechnology, Inc. (PBYI) | CEO | $757,260 | $6,152,550 |
| 2017 | Puma Biotechnology, Inc. (PBYI) | CEO | $732,527 | $2,787,885 |
